Frequency of the Metabolic Syndrome and Association with Survival in Newly Diagnosed GBM Patients: A Retrospective Review (P07.106)

Abstract

Objective: Report the frequency of metabolic syndrome (MS) in newly-diagnosed glioblastoma (NGBM) patients and impact of MS on patient survival. Background The MS is a well-established risk factor for atherosclerotic cardiovascular and cerebrovascular disease. It has been identified as a risk factor for some systemic cancers and as a predictor of worse clinical outcome in systemic cancer. There is limited evidence for obesity and hyperglycemia as predictors of poor outcome in malignant glioma patients (Chambless 2011). The frequency of MS and its impact on survival of NGBM patients has not been determined. Design/Methods: We retrospectively reviewed records of all patients (N = 114) with NGBM at University Hospitals Case Medical Center from 2007-2011. Criteria for MS included > 3 of elevated fasting glucose, hypertension, elevated triglycerides, reduced high density lipoprotein C (or history of these or history of treatment for them), and obesity. The criteria had to be present prior to diagnosis of GBM. Results: MS was identified in 44/114 patients (39%). Mean patient age was 65 years (67 with MS, 64 without MS). The majority received radiation, typically with temozolomide. Median survival by MS status was 7 months for those with MS and 12 months for those without MS (p = 0.0456). After adjustment for other prognostic factors, median survival was shorter for those with MS (8 months) versus those without (10 months), but this did not reach statistical significance (p > 0.05). Conclusions: MS was identified in 39% of NGBM. The presence of MS was associated with an unadjusted lower median survival compared to patients without MS. After adjustment for independent prognostic factors, this survival difference was not significant. Because of potential limitations due to the retrospective design of this study, we will perform a prospective study to determine the impact of MS on survival of NGBM patients. Disclosure: Dr. Rogers has received personal compensation for activities with Sigma Tau Pharmaceuticals as a speaker. Dr. Vengoechea has nothing to disclose. Dr. Ostrom has nothing to disclose. Dr. Chen has nothing to disclose. Dr. Davitkov has nothing to disclose. Dr. Strodtbeck has nothing to disclose. Dr. Selman has nothing to disclose. Dr. Gerson has nothing to disclose. Dr. Nock has nothing to disclose. Dr. Machtay has nothing to disclose. Dr. Lo has nothing to disclose. Dr. Sloan has received personal compensation for activities with RealBio and Nanotech Solutions. Dr. Sloan has received research support from the NIH, Lentigen, RealBio, Nantech, Genentech, the Cristal Chair, and the Kimble Foundation. Dr. Barnholtz-Sloan has nothing to disclose.